search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


TARC IN PATIENTS WITH LYMPHADENOPATH, FEVER OR NON-HODGKIN LYMPHOMA


- candidate number26624
- NTR NumberNTR6994
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR2-feb-2017
- Secondary IDs 
- Public TitleTARC IN PATIENTS WITH LYMPHADENOPATH, FEVER OR NON-HODGKIN LYMPHOMA
- Scientific TitleTARC-002 EVALUATION OF THYMUS AND ACTIVATION REGULATED CHEMOKINE (TARC) IN PATIENTS WITH LYMPHADENOPATHY , FEVER OR NON-HODGKIN LYMPHOMA
- ACRONYMTARC-002
- hypothesisThe hypotheses of the study is that TARC levels in patients with fever, other causes of lymphadenopathy and non-Hodgkin lymphoma will be significantly lower compared to patients with Hodgkin lymphoma.
- Healt Condition(s) or Problem(s) studiedFever, Non Hodkin's lymfoma (NHL), Lymphadenopathy
- Inclusion criteriaIn order to be eligible to participate in this study, a subject must meet all of the following criteria: - Age 18 years; - Ability to give written informed consent; And one of the following: (1) Lymph node enlargement of unknown cause for whicha diagnostic fine needle aspiration will be performedor (2) Presenting with fever at the emergency department or (3) Presenting with newly diagnosed or relapsed nodular lymphocyte predominant or non-Hodgkin lymphoma.
- Exclusion criteriaA potential subject who meets any of the following criteria will be excluded from participation in this study (applicable to all subgroups): - Ineligibility to give written informed consent; - Patients with active atopic disease or hepatic failure; - Patients already diagnosed with Hodgkin lymphoma
- mec approval receivedyes
- multicenter trialno
- randomisedno
- groupFactorial
- TypeSingle arm
- Studytypeintervention
- planned startdate 1-apr-2017
- planned closingdate31-mrt-2020
- Target number of participants300
- InterventionsICF, venapunction once 10ml
- Primary outcomeMean TARC levels (pg/mL) in correlation with final diagnosis
- Secondary outcome Not applicable
- Timepointsat entry
- Trial web sitetoetsingonline.nl
- statusplanned
- CONTACT FOR PUBLIC QUERIESdrs. W.J. Plattel
- CONTACT for SCIENTIFIC QUERIESdrs. W.J. Plattel
- Sponsor/Initiator University Medical Center Groningen (UMCG)
- Funding
(Source(s) of Monetary or Material Support)
University Medical Center Groningen (UMCG)
- Publications
- Brief summaryThis is a prospective study to determine TARC levels in patients with lymph node enlargement of unknown origin, fever and in patients who are already diagnosed with non-Hodgkin lymphoma subtypes. TARC levels will be matched with final diagnosis and compared with TARC levels of healthy controls and patients with Hodgkin lymphoma, which have already been collected in previous studies.
- Main changes (audit trail)Ontbrekende informatie niet aangeleverd door onderzoeker.
- RECORD2-feb-2017 - 8-feb-2018


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl